The European Medicines Agency (EMA) has granted orphan medicinal product (orphan drug) designation to Tocagen’s Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine) for the treatment of patients with glioma, a type of brain tumor.    Toca 511 & Toca FC is currently under evaluation in a global Phase 3 trial, called Toca 5, involving patients with first or second recurrence of high-grade glioma (HGG), namely glioblastoma or anaplastic astrocytoma, who are undergoing resect...